Lung microbiome: new insights into the pathogenesis of respiratory diseases.

Li R, Li J, Zhou X. · 2024

Read Lung microbiome: new insights into the pathogenesis of respiratory diseases. by Li R, Li J, Zhou X. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10791971.txt.

Introduction

Li and colleagues review what lives in our lungs and why it matters in this 2024 paper. Lungs were long thought to hold no microbes at all, meaning no tiny living things. Better tests showed a small, shifting community does live there. It comes mostly from the mouth and throat, and it is kept sparse by coughing, immune cells, and the sweep of tiny hairs in the airways.

The review links this lung community to the gut and to the immune system. It then walks through roles in asthma, chronic lung disease, scarring, pneumonia, COVID-19, and lung cancer. The authors note that fungi and viruses in the lung are still poorly studied. They suggest that learning to steer this community could one day aid treatment, but much basic work remains.

Catalog record

CREATORLi R, Li J, Zhou X.
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE207 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10791971

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Lung microbiome: new insights into the pathogenesis of respiratory diseases By Ruomeng Li, Jing Li, Xikun Zhou Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01722-y ABSTRACT Abstract The lungs were long thought to be sterile until technical advances uncovered the presence of the lung microbial community. The microbiome of healthy lungs is mainly derived from the upper respiratory tract (URT) microbiome but also has its own characteristic flora. The selection mechanisms in the lung, including clearance by coughing, pulmonary macrophages, the oscillation of respiratory cilia, and bacterial inhibition by alveolar surfactant, keep the microbiome transient and mobile, which is different from the microbiome in other organs. The pulmonary bacteriome has been intensively studied recently, but relatively little research has focused on the mycobiome and virome. This up-to-date review retrospectively summarizes the lung microbiome’s history, composition, and function. We focus on the interaction of the lung microbiome with the oropharynx and gut microbiome and emphasize the role it plays in the innate and adaptive immune responses. More importantly, we focus on multiple respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), fibrosis, bronchiectasis, and pneumonia. The impact of the lung microbiome on coronavirus disease 2019 (COVID-19) and lung cancer has also been comprehensively studied. Furthermore, by summarizing the therapeutic potential of the lung microbiome in lung diseases and examining the shortcomings of the field, we propose an outlook of the direction of lung microbiome research. Subject terms: Microbiology, Respiratory tract diseases, Inflammation, Lung cancer, Prognostic markers INTRODUCTION With the Human Microbiome Project, the human body’s microbiome has gradually been unveiled.1 The microbiome includes all the microbes and their gene sequences (including homologous sequences) in a specific habitat at a specific time.2,3 It contains every organism, including not only bacteria but also archaea, fungi, and viruses. Various methods of obtaining DNA (metagenomics), RNA, metabolites, and proteins have been reported.4–6 In the past, the oropharyngeal microbiome and the gut microbiome have been studied with great enthusiasm, but the sterile environment of the lungs has been inherently perceived. The lung microbiome has thus gone unnoticed by the world. However, with the application of detection technologies, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and the maturation of DNA sequencing,7,8 researchers began to pay attention to the lung microbiome. The lung microbiome is mostly composed of bacteria, fungi, and viruses.9,10 The relationship between the lung microbiome and the oropharyngeal and gut microbiomes, especially the gut-lung axis, has been intensively studied. The gut-lung axis is bidirectional and influences the progression of intestinal and lung diseases in terms of metabolism, immunity, and other aspects. Although the exact mechanism is unknown, the lung microbiome has an impact on lung development. Germ-free rodents tend to have reduced lung parenchyma and less developed alveoli.11 The dominant population and abundance of the microbiome differ in healthy and diseased lungs. Even the composition and size of the lung microbiome change dynamically under the influences of different kinds of diseases. For instance, in patients with asthma and COPD, pathogenic Proteobacteria, especially Haemophilus, were increased, whereas in cystic fibrosis (CF) patients, Candida albicans was increased.12–14 It follows that dysbiosis in the pulmonary microbiome, which imbalances the composition and size of the lung microbiome, affects disease occurrence, progression, and prognosis.15 Therefore, the lung microbiome can be considered an indicator of disease and diagnosis. In addition, due to their geographical location, the lung microbiome is strongly related to the oropharyngeal and gut microbiomes. Numerous cases have confirmed the interaction between oral, gut, and lung microbes.16–18 If oral microorganisms enter the lungs and spread, they can directly form the lung microbial community and directly affect the growth of lung bacteria. However, this may lead to contamination of bronchoalveolar lavage fluid (BALF), causing limitations in the experimental results.19–21 To address this issue, sampling of the lung microbiome requires strict negative control methods16,22 and protective bronchial sampling techniques such as wax-sealed catheters.23 Since 2020, COVID-19 has broken out around the world, causing great damage to people’s health. Due to the constant changes in the coronavirus, it is clinically impossible to contain the infection and spread of the virus from the source. Researchers have provided insights into the link between the lung microbiome and this pandemic, and the results have been encouraging. By 2022, research on the lung microbiome will also gradually become linked to cancer. Changes in the lung microbiome are related to lung cancer occurrence, development, and prognosis. The lung microbiome composition differs between states, such that Streptococci and Staphylococci are more abundant in cancer patients, while the opposite is true in noncancerous subjects.24 Pulmonary microorganisms and their products affect clinical treatments, especially immunotherapy. Both immunotherapy and prognostic outcomes decreased with altered microbial abundance. Combining microbial therapy with lung cancer treatment may lead to an improvement in efficacy. With technological progress, mysteries about the lung microbiome are gradually being unveiled. Studying microbial communities will further clarify the pathogenesis and development of many diseases. We will examine the history of the lung microbiome, the effects of the interactions between microbes and host factors, and explore new research directions. HISTORY OF THE LUNG MICROBIOME The study of the lung microbiome is still in its infancy compared to that of the microbiomes of other parts of the body. In early years, scientists began investigating the effect of colonization on pulmonary allergy symptoms.25 However, most of the subsequent studies focused on the functions of the gut microbiome, fecal microbiome, etc., in the lung.26 It was evident that the lungs were in a sterile state, which was the perception of most people at that time. In 2010, researchers successively determined the composition of the airway microbiota; thus, the microbiome in the respiratory system came to light.27 With further advances in detection technology, scientists have applied computed tomography (CT) scans, PCR, and 16S rRNA sequencing to investigate the lung microbiome.8,28 Since 2011, the relationship between various lung diseases and microbiomes has been gradually explored. The presence of a microbiome in COPD patients has been found.3 At the same time, Foder et al. found that adult CF is closely related to the microbiome.29 Not only are the survival and prognosis of patients with COPD related to lung microorganisms,30 but pneumonia31 and bronchial diseases32,33 also involve an imbalance in pulmonary microorganisms. In 2014, researchers focused on the relationship between lung transplantation and the microbiome, showing that the impact of the lung microbiome on innate and adaptive immune responses is beginning to be explored.34,35 With the further elaboration of the concept of the “microbiome”, the focus is no longer limited to bacterial communities but also to fungal and viral communities. For example, Nguyen et al. uncovered the impact and significance of pulmonary fungal communities on respiratory diseases.36 In 2016, Segal et al. linked the lung microbiome to HIV.37 After that, with the maturation of molecular diagnostic techniques, one could precisely characterize and analyze the distribution of the lung microbiome. Relationships between pneumonia, COPD, CF, and microorganisms were further investigated. At the same time, new research areas, such as those involving tuberculosis and sepsis, have been developed.16,38 In 2016, the association between intrinsic immunity and microorganisms in the body was explored.39 The same lung microbiome is involved in acute respiratory distress syndrome (ARDS) and hematopoietic stem

Read the complete text